Neurodegenerative Disorder Therapeutics Market Revenue Anticipated to Reach $34.13 Billion by 2030 at 9.6% CAGR
The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Expected Market Size Of The Neurodegenerative Disorder Therapeutics Market From 2026 To 2030?
The neurodegenerative disorder therapeutics market size has shown robust growth in recent years. It is anticipated to expand from $21.66 billion in 2025 to $23.65 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.2%. This historical growth can be ascribed to several factors, including the increasing incidence of neurodegenerative disorders, a growing elderly population, restricted availability of treatment options, greater awareness leading to early diagnosis, and enhancements in hospital and neurology care infrastructure.
The neurodegenerative disorder therapeutics market size is anticipated to experience robust expansion in the coming years. It is forecast to achieve a value of $34.13 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.6%. This projected growth throughout the forecast period stems from factors such as the development of gene therapies, advancements in monoclonal antibody treatments, the integration of AI-based diagnostics and monitoring, increased investment in clinical research and trials, and the expansion of personalized medicine and targeted therapeutics. Prominent trends for the forecast period include the rising adoption of neuroprotective and neurorestorative therapies, a greater focus on symptom management and patient-centric care, an increase in clinical trials for novel neurodegenerative drugs, the broadening of personalized and targeted therapeutic approaches, and the integration of home care and remote monitoring solutions.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2818&type=smp
What Key Drivers Are Influencing The Growth Of The Neurodegenerative Disorder Therapeutics Market?
Heightened investment in research and development (R&D) for neurodegenerative disorder therapeutics is expected to propel the growth of the neurodegenerative disorder therapeutics market moving forward. Governments and organizations initiate investments in research and development for neurodegenerative disorders for various compelling reasons, including their increasing prevalence, significant unmet medical needs, economic repercussions, global health initiatives, and more. For instance, in March 2023, according to Government of Canada, a Canada-based federal administration, the government of Canada revealed a $38.3 million investment in 2023 aimed at advancing research into neurodegenerative diseases. Therefore, increasing investment in research and development (R&D) for neurodegenerative disorder therapeutics will continue to drive the growth of the neurodegenerative disorder therapeutics market in the forecast period.
Which Segments Are Included In The Analysis Of The Neurodegenerative Disorder Therapeutics Market?
The neurodegenerative disorder therapeutics market covered in this report is segmented –
1) By Indication Type: Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types
2) By Drug Type: N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types
3) By Distribution: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Parkinson’s Disease: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics
2) By Alzheimer’s Disease: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Anti-Amyloid Monoclonal Antibodies
3) By Multiple Sclerosis: Immunomodulators, Immunosuppressants, Corticosteroids
4) By Huntington’s Disease: Tetrabenazine, Antipsychotic Medications
5) By Other Indication Types: Amyotrophic Lateral Sclerosis (ALS) Treatments, Frontotemporal Dementia Treatments, Prion Disease Treatments
Which Trends Are Impacting The Growth Of The Neurodegenerative Disorder Therapeutics Market?
Major companies operating in the neurodegenerative disorder therapeutics market are focusing on developing innovative treatment options, such as prodrug formulations, to enhance the bioavailability, efficacy, and safety profile of Parkinson’s disease therapies. Prodrugs are inactive compounds that are metabolically converted into active drugs in the body, allowing for controlled and sustained delivery of therapeutic agents. For instance, in January 2024, AbbVie Inc., a US-based biopharmaceutical company, launched PRODUODOPA (foslevodopa or foscarbidopa) in the European Union for people living with advanced Parkinson’s disease. The therapy utilizes a soluble prodrug combination to provide continuous levodopa delivery, aiming to reduce motor fluctuations and improve patients’ quality of life. This launch represents a significant advancement in managing advanced Parkinson’s disease by offering an alternative to intermittent oral dosing and improving treatment adherence.
Which Key Industry Participants Are Active In The Neurodegenerative Disorder Therapeutics Market?
Major companies operating in the neurodegenerative disorder therapeutics market are Biogen Inc., Pfizer Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann-La Roche Ltd., ACADIA Pharmaceuticals Inc., H. Lundbeck A/S, Boehringer Ingelheim International GmbH, Merck Serono S.A., Orion Corporation, Mitsubishi Tanabe Pharma America, Allergan PLC, GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Celgene Corporation, Bayer Schering Pharma AG, AstraZeneca plc, Alector Inc., Yumanity Therapeutics Inc., Eisai Co. Ltd., Bristol Myers Squibb Company, Amylyx Pharmaceuticals Inc., Genentech Inc., AC Immune SA, Annexon Bioscience Inc., BioArctic Neuroscience AB, Cajal Neuroscience Inc., Cognito Therapeutics Inc., Grifols S.A., New Equilibrium Biosciences Inc., Prothena Corporation PLC, Tessera Therapeutics Inc., Vigil Neuroscience Inc.
Read the full neurodegenerative disorder therapeutics market report here:
Which Region Is Expected To Register The Fastest Growth In The Neurodegenerative Disorder Therapeutics Market?
North America was the largest region in the global neurodegenerative disorder therapeutics market in 2025. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the neurodegenerative disorder therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Neurodegenerative Disorder Therapeutics Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=2818&type=smp
Browse Through More Reports Similar to the Global Neurodegenerative Disorder Therapeutics Market 2026, By The Business Research Company
Neurology Devices Market Report 2026
https://www.thebusinessresearchcompany.com/report/neurology-devices-global-market-report
Interventional Neurology Devices And Equipment Market Report 2026
Neurosurgery Devices And Equipment Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
